The Asian Journal of Oncology (ASJO) is an open-access, peer-reviewed journal dedicated to all sub speciality of oncology including medical surgical radiation molecular and nuclear oncology and allied sciences. Established in 2015 by the Spring Hope Cancer Foundation, it transitioned to continuous publication in 2023 due to a surge in global submissions, particularly from South-East Asia. The journal, under the ownership of the Spring Hope Cancer Foundation and published by Scientific Scholar, focuses on disseminating high-quality original investigations, articles, and reviews on emerging technologies and therapeutic interventions in oncotherapy and related surgeries.
The editorial comprised more than 200 oncologists from across the globe.
The audience comprises researchers all sub speciality of oncology including medical surgical radiation molecular and nuclear oncology and allied sciences. ASJO boasts a rigorous double-blind peer-review process to ensure scientific accuracy and relevance, with transparency in authors' disclosures of conflicts and affiliations. The editorial board, consisting of experts from medical and allied sciences, oversees content clarity and journal focus. Dr. Sajjan Rajpurohit Director & HOD Medical Oncology,
BLK-Max Super Speciality Hospital at Rajendra Place &, Max Hospital at Shalimar Bagh. New Delhi, India, serves as the Editor-In-Chief.
Benefits of the ASJO:
An article published in the journal can be viewed without a fee by readers all over the world. The author also gets to retain copyright to the article and the figures. This allows authors to extend their exposure in the world of medical research and get worldwide recognition for their work.
Abstracting and Indexing Information
The journal is registered with the following abstracting partners:
EMBASE/ Excerpta Medica, Google Scholar, CrossRef, ReadCube
ASJO's continuous publication model allows articles to be accessible worldwide without fees, granting authors copyright retention and global recognition. The journal is indexed by EMBASE/Excerpta Medica, Google Scholar, CrossRef, and ReadCube, contributing to its standing in the academic community. Overall, ASJO serves as a valuable platform for the global exchange of clinical knowledge and research in the field of oncology.
Journal Ethics
The Asian Journal of Oncology is committed to meeting and upholding the standards of ethical behavior at all stages of the publication process. We follow closely the industry associations, such as the Committee on Publication Ethics (COPE), International Committee of Medical Journal Editors (ICMJE) and World Association of Medical Editors (WAME), that set standards and provide guidelines for best practices in order to meet these requirements. For a summary of our specific policies regarding duplicate publication, conflicts of interest, patient consent, etc., please visit our Ethical Guidelines section
Plagiarism Policy
The journal uses plagiarism check software (iThenticate) on the Editor’s and Reviewer’s panel in the manuscript management system which is used to check and control Plagiarism for each article. Any manuscript, that is found to have plagiarism is rejected.
The Asian Journal of Oncology (ASJO), established by the Spring Hope Cancer Foundation, is a globally recognized, open-access journal publishing high-quality research in oncology. With a continuous publication model and rigorous peer-review process, ASJO ensures scientific accuracy. Dr. Sajjan Rajpurohit, Editor-In-Chief, leads a diverse editorial board of over 200 oncologists. The journal's commitment to ethical standards and plagiarism prevention is evident in its affiliations with industry associations. ASJO's open-access policy, indexed by major databases, facilitates global accessibility. Recent publications cover diverse topics, showcasing the journal's multidisciplinary approach. The Spring Hope Foundation contributes significantly to cancer research, addressing challenges through breakthroughs, clinical trials, and innovative technologies. Their impact is evident in promising outcomes, patient-centric clinical trials, and the integration of cutting-edge technologies in cancer diagnosis.
Newsletter
